The Study of Irinotecan Plus Epirubicin as the Second-line Chemoregime for Advanced Gastric Cancer

• Status: Unknown status
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is to determine the response rate and safety profile of irinotecan plus epirubicin as the second-line chemotherapy for advanced gastric cancer and fully evaluate the feasibility and effectiveness of the regime.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Anhui Medical University
• Treatments: Camptothecin; Epirubicin; Irinotecan

Criteria

Inclusion criteria:

• Aged between 18 to 70 years

• The pathologically confirmed gastric adenocarcinoma and the failure of first-line chemotherapy

• Measurable lesions outside the stomach

• ECOG(Eastern Cooperative Oncology Group ) score between 0 to 1

• Expected survival time of at least 3 months

• Subjects receiving treatment for other damage caused has been restored, which it accepted the nitroso or mitomycin interval> 6 weeks, the acceptance of other cytotoxic drugs, radiotherapy or surgery> = 4 weeks, and the wound has completely healed. No bleeding, no nervous system transferred

• Blood and organ function was normal

Exclusion criteria:

• Comorbid with other malignant tumors

• Pregnant and lactating women

• with the disease of endangering patient's safety and affecting the completion of the study

• Patients suffering from high blood pressure by antihypertensive treatment cannot control (systolic blood pressure> 140mmhg, diastolic blood pressure> 90mmhg,) there is more than Class I and Class I arrhythmia coronary heart disease, with more than Class I heart dysfunction

• Major organ failure, such as decompensated heart and lung failure, liver failure, renal failure and patients with intestinal obstruction ipate in other clinical trials of patients in the past four weeks

• Participated in clinical trials with other drugs or using other drugs during past 4 weeks

• Lesions which can't be measured such as pleural effusion, ascites, peritoneal cancer lesions, diffuse liver and bone metastases violation, brain metastasis